RAY-B 📈 RaySearch Laboratories AB - Overview
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0000135485
RAY-B: Oncology, Software, Radiation, Therapy, Treatment, Planning, Systems
RaySearch Laboratories AB (publ) is a medical technology company that specializes in providing innovative software solutions for cancer care, with a global presence spanning the Americas, Europe, Africa, the Asia-Pacific, and the Middle East. The company's product portfolio includes RayStation, a comprehensive treatment planning system for radiation therapy that enables personalized treatment plans, as well as RayCare, an oncology information system designed to streamline clinical activities and enhance patient care. Additionally, RaySearch offers RayIntelligence, a cloud-based analytics system that utilizes data analytics and machine learning to monitor and improve cancer therapy outcomes.
RaySearch's product line also includes RayCommand, a treatment control system that acts as a critical link between the treatment machine and the treatment planning and oncology information systems, ensuring seamless integration and efficient workflow. Furthermore, the company provides RayPlan, a treatment planning system that supports a range of treatment planning activities for various radiation therapy modalities, including 3D-CRT, IMRT, VMAT, and electron beam radiation therapy. For research applications, RaySearch offers µ-RayStation, a software platform designed for planning and evaluation in small animal irradiation research, facilitating advancements in cancer research and development.
As a leading player in the health care technology industry, RaySearch Laboratories AB (publ) is headquartered in Stockholm, Sweden, and is listed on the stock exchange with the ISIN code SE0000135485. The company's common stock is classified under the GICS Sub Industry: Health Care Technology, reflecting its focus on developing and marketing innovative software solutions for the health care sector. With its strong online presence, including its website at https://www.raysearchlabs.com, RaySearch is well-positioned to continue driving growth and innovation in the medical technology industry.
Additional Sources for RAY-B Stock
RAY-B Stock Overview
| Market Cap in USD | 640m |
| Sector | Healthcare |
| Industry | Health Information Services |
| GiC Sub-Industry | Health Care Technology |
| IPO / Inception |
RAY-B Stock Ratings
| Growth 5y | 47.2% |
| Fundamental | 73.3% |
| Dividend | 4.41% |
| Rel. Strength Industry | 5317 |
| Analysts | - |
| Fair Price Momentum | 209.11 SEK |
| Fair Price DCF | 268.90 SEK |
RAY-B Dividends
| Dividend Yield 12m | 0.34% |
| Yield on Cost 5y | 0.63% |
| Annual Growth 5y | % |
| Payout Consistency | 5.9% |
RAY-B Growth Ratios
| Growth Correlation 3m | 87.4% |
| Growth Correlation 12m | 95.5% |
| Growth Correlation 5y | 28.7% |
| CAGR 5y | 13.03% |
| CAGR/Mean DD 5y | 0.47 |
| Sharpe Ratio 12m | 2.07 |
| Alpha | 107.43 |
| Beta | 0.91 |
| Volatility | 36.25% |
| Current Volume | 59.7k |
| Average Volume 20d | 76k |
As of December 22, 2024, the stock is trading at SEK 204.00 with a total of 59,679 shares traded.
Over the past week, the price has changed by +0.99%, over one month by +5.13%, over three months by +23.79% and over the past year by +126.30%.
Yes, based on ValueRay Fundamental Analyses, RaySearch Laboratories AB (ST:RAY-B) is currently (December 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 73.25 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RAY-B as of December 2024 is 209.11. This means that RAY-B is currently overvalued and has a potential downside of 2.5%.
RaySearch Laboratories AB has no consensus analysts rating.
According to ValueRays Forecast Model, RAY-B RaySearch Laboratories AB will be worth about 230.9 in December 2025. The stock is currently trading at 204.00. This means that the stock has a potential upside of +13.17%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 260 | 27.5% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 230.9 | 13.2% |